Similarly, the EASL guidelines recommend pharmacotherapy for patients with progressive NASH (bridging fibrosis and cirrhosis), as well as for early-stage NASH with high inflammatory activity and/or those with increased risk of fibrosis progression (i.e., age >50 years; diabetes, metabolic syndrome, increased ALT) [10]. This evidence concerns the gene GPT and metabolic dysfunction-associated steatohepatitis.